Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2024-06-26 00:00:00 ET · period of report 2024-06-24 · accession 0000950170-24-077944 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-06-26 | 2024-06-24 | FDMT | Kirn David | CEO, Dir | S - Sale+OE | $23.10 | -12.9K | 1.06M | -1% | -$298.7K |
| DT | 2024-06-26 | 2024-06-24 | FDMT | Kirn David | CEO, Dir | M - OptEx | $14.42 | +12.9K | 1.07M | +1% | +$186.5K |
| DT | 2024-06-26 | 2024-06-24 | FDMT | Kirn David | CEO, Dir | M - OptEx | $0.00 | -12.9K | 577.1K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-24 | S | D | 12,930 | $23.10 | 1,059,153 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $22.69 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-06-24 | M | A | 12,930 | $14.42 | 1,072,083 | D | — | — | |
| 3 | Derivative | Stock Option (Right To Buy) | 2024-06-24 | M | D | 12,930 | $0.00 | 577,070 | D | $14.42 · — to 2033-12-10 | 12,930 Common Stock | (F3) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |